Skip to main content
OpenTrials
Completed

NCT Number: NCT06190392

Effect of a Global Simplified Strategy on Thromboembolic Events in Emergency Department Patients with Suspected Pulmonary Embolism

Pulmonary embolism (PE) is frequently suspected in emergency departments (ED) patients which often leads to the prescription of DDimer testing and irradiative chest imaging (Computed Tomographic Pulmonary Angiogram CTPA in most cases).[1] Indeed, an increased use of CTPA has been reported without clear benefit in terms of prognosis.This increased use is reportedly associated with potential overdiagnosis of PE, increased cost, length of ED stay, and side effects from both chest imaging and undue anticoagulant treatments. The standard diagnostic strategy for PE work up includes three steps with an initial evaluation of clinical probability, followed by D-dimer testing if indicated, followed by chest imaging if necessary - Computed tomographic pulmonary angiogram CTPA being the imaging modality of choice.

A large European prospective study has reported that the use of CTPA has constantly increased without change in the diagnostic yield. In order to reduce the use of CTPA, it has been validated that in patients with a low likelihood of PE, the D-dimer threshold for ordering CTPA can be raised at 1000 ng/ml. It has been validated that a low likelihood of PE can be determined either with the YEARS or the PEGeD clinical decision rules. These latter two include one common item being "Is PE the most likely diagnosis". A retrospective cohort study of 3330 patients reported that using this sole question of "Is PE the most likely diagnosis" can be safely used to raise the D-dimer threshold to 1000 ng/ml, and that this performs as well as YEARS and PEGeD. This simple question is easier to use by emergency physicians compared to complex ones, which are reportedly seldom used by emergency physicians. Therefore, the validation of the "PE unlikely" simple and straightforward decision rule could increase physicians' adherence and therefore limit the use of chest imaging.

The hypothesis of this prospective study is that the likelihood of PE assessed to elevate the DDimer threshold to 1000 ng/ml can be estimated by the sole question of "is PE the most likely diagnosis", and to validate a global simplified diagnostic strategy for PE in the ED.

The intervention will be the patient's management with a simplified global strategy. Whether PE is the most likely diagnostic will be assessed by the unstructured implicit clinician's estimation.

In patient with a clinical suspicion of pulmonary embolism: DDimer testing will be performed.

If the likelihood of PE is low (PE is not the most likely diagnosis), then threshold for DDimer testing will be 1000 ng/ml. If the likelihood of PE is high (PE is the most likely diagnosis), then the age-adjusted DDimer threshold will be applied.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Emergency department Hospital Pitié-Salpêtrière

Paris, 75013, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years
  • ED adult patients with suspected pulmonary embolism defined as:
  • New onset of or worsening shortness of breath
  • Or Chest pain
  • Or Syncope in the absence of any obvious other cause (such as pneumothorax, asthma attack, ST elevation myocardial infarction, trauma, etc.)
  • Patient able to understand and give oral consent
  • Informing and obtaining the patient's oral consent
  • Social security affiliation (except AME)

Exclusion criteria

  • Patients currently treated with full-dose anticoagulant therapy
  • Diagnosed thrombo-embolic event in the past 6 months
  • PE ruled out by the PERC rule (low clinical probability and none of the 8 items of the PERC score)
  • Acute severe presentation (clinical signs of respiratory distress, hypotension, SpO2 < 90%, shock)
  • DDimer level known before ED visit
  • Patient living in assisted-living home or nursing home or palliative center. Anticipated life expectancy < 3 months or "do not resuscitate" order
  • Patient under legal protection measure (tutorship or curatorship) and patient deprived of freedom
  • Pregnancy and breastfeeding
  • Participation in another interventional trial

Treatment and study plan

MODS Modified simplified diagnostic strategy

Other

The intervention will be the patient's management with a simplified global strategy. Whether PE is the most likely diagnostic will be assessed by the unstructured implicit clinician's estimation.

In patient with a clinical suspicion of pulmonary embolism: DDimer testing will be performed.

If the likelihood of PE is low (PE is not the most likely diagnosis), then threshold for DDimer testing will be 1000 ng/ml. If the likelihood of PE is high (PE is the most likely diagnosis), then the age-adjusted DDimer threshold will be applied.

Primary outcomes

  1. The failure proportion of the diagnostic strategy, defined as a diagnosed thrombo-embolic event at 3 months follow-up (either a PE or a deep venous thrombosis), among patients in whom PE was initially ruled out.

    Time frame: 3 months

Secondary outcomes

  1. Pulmonary embolism

    Time frame: 3 months

  2. Deep venous thrombosis

    Time frame: 3 months

  3. CTPA or V/Q scan ordered by ED physicians

    Time frame: 3 months

  4. Type of PE (lobar, segmental, sub-segmental)

    Time frame: 3 months

  5. Hospital admission following the ED visit

    Time frame: 3 months

  6. Anticoagulant therapy administration,

    Time frame: 3 months

  7. All-cause mortality

    Time frame: 3 months

  8. All-cause readmissions at 3 months

    Time frame: 3 months

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Registry information

Acronym: MODS STRATEGY

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jan 5, 2024
Registry last updated
Feb 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.